Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Should l Buy ATRC?
Source: NASDAQ.COM
Stock Performance and Analyst Predictions: AtriCure (ATRC) shares have risen 3.5% recently, with Wall Street analysts projecting a mean price target of $51.44, suggesting a potential upside of 36.3%. The price targets range from $40.00 to $64.00, indicating varying levels of optimism among analysts.
Skepticism Towards Price Targets: While price targets are popular among investors, they can often mislead, as analysts may set overly optimistic targets due to business incentives. A low standard deviation in price targets indicates strong agreement among analysts, but it should not be the sole basis for investment decisions.
Earnings Estimate Revisions: Analysts have shown increased optimism regarding AtriCure's earnings, with a 32.9% rise in the Zacks Consensus Estimate for the current year. This trend in earnings estimate revisions is correlated with potential stock price movements.
Zacks Rank and Investment Outlook: AtriCure holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates. This ranking, along with a strong track record, suggests a favorable outlook for the stock despite the skepticism surrounding price targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRC
Wall Street analysts forecast ATRC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.260
Low
45.00
Averages
52.20
High
64.00
Current: 28.260
Low
45.00
Averages
52.20
High
64.00
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
AtriCure Chief Scientific Officer Sells 5,000 Shares Amid Negative Returns
- Insider Transaction Overview: On March 12, 2026, AtriCure's Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares valued at $149,150, reducing his direct holdings to 96,875 shares with a post-transaction value of $2.86 million, reflecting a concerning backdrop of a -9.67% total return over the past year.
- Transaction Scale Analysis: This sale marks Vinayak's largest transaction in the past year, surpassing his previous two sales of 2,500 shares each in May and August 2025, indicating a more aggressive approach to reducing his stake, although he still maintains a significant overall position.
- Market Environment Impact: At the time of the transaction, AtriCure's shares were priced at $29.83, closing at $29.54 on the transaction date, highlighting the company's underperformance in the market, and Vinayak's sale occurring during a downturn may reflect uncertainties about future market conditions.
- Investor Considerations: Shortly before this sale, Vinayak received approximately 45,000 shares in restricted stock and performance awards, transferring about 15,600 shares for tax withholding; while this transaction accounted for 4.91% of his direct holdings, his overall stake remains substantial, prompting investors to consider his continued commitment to the company he helps lead.
See More
ATRICURE INC: UBS Lowers Price Target to $55 from $60
- Price Adjustment: AtriCure has reduced its target price from $60 to $55.
- Market Impact: This adjustment may reflect changes in market conditions or company performance expectations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Changes in analyst ratings may lead to short-term volatility in the affected stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Impact of Rating Changes: Upgrades typically boost investor confidence and may drive stock prices higher, while downgrades can trigger sell-offs, impacting company valuations, necessitating careful evaluation by investors.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for broader market insights.
See More
AtriCure Reports Strong Q4 2025 Earnings with 15% Revenue Growth
- Significant Revenue Growth: AtriCure reported total revenue of $534 million for 2025, reflecting a 15% increase over 2024, showcasing strong performance across multiple business segments, particularly following new product launches that are expected to further drive future revenue growth.
- Improved Profitability: The company achieved nearly $62 million in adjusted EBITDA and generated $45 million in cash for 2025, indicating a substantial enhancement in profitability and cash flow, which provides financial support for future investments and expansion.
- Clinical Trial Progress: The completion of enrollment in the LeAAPS clinical trial with over 6,500 patients and the initiation of the BoxX-NoAF trial are expected to provide critical data for future product development and market promotion, further solidifying AtriCure's market position.
- Optimistic Outlook: Management projects revenue growth of 12% to 14% for 2026 and reaffirms an adjusted EBITDA target between $80 million and $82 million, reflecting confidence in future growth despite competitive pressures and uncertainties in international markets.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
AtriCure Chief Scientific Officer Sells 5,000 Shares Amid Negative Returns
- Insider Transaction Overview: On March 12, 2026, AtriCure's Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares valued at $149,150, reducing his direct holdings to 96,875 shares with a post-transaction value of $2.86 million, reflecting a concerning backdrop of a -9.67% total return over the past year.
- Transaction Scale Analysis: This sale marks Vinayak's largest transaction in the past year, surpassing his previous two sales of 2,500 shares each in May and August 2025, indicating a more aggressive approach to reducing his stake, although he still maintains a significant overall position.
- Market Environment Impact: At the time of the transaction, AtriCure's shares were priced at $29.83, closing at $29.54 on the transaction date, highlighting the company's underperformance in the market, and Vinayak's sale occurring during a downturn may reflect uncertainties about future market conditions.
- Investor Considerations: Shortly before this sale, Vinayak received approximately 45,000 shares in restricted stock and performance awards, transferring about 15,600 shares for tax withholding; while this transaction accounted for 4.91% of his direct holdings, his overall stake remains substantial, prompting investors to consider his continued commitment to the company he helps lead.
See More
ATRICURE INC: UBS Lowers Price Target to $55 from $60
- Price Adjustment: AtriCure has reduced its target price from $60 to $55.
- Market Impact: This adjustment may reflect changes in market conditions or company performance expectations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Changes in analyst ratings may lead to short-term volatility in the affected stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Impact of Rating Changes: Upgrades typically boost investor confidence and may drive stock prices higher, while downgrades can trigger sell-offs, impacting company valuations, necessitating careful evaluation by investors.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for broader market insights.
See More
AtriCure Reports Strong Q4 2025 Earnings with 15% Revenue Growth
- Significant Revenue Growth: AtriCure reported total revenue of $534 million for 2025, reflecting a 15% increase over 2024, showcasing strong performance across multiple business segments, particularly following new product launches that are expected to further drive future revenue growth.
- Improved Profitability: The company achieved nearly $62 million in adjusted EBITDA and generated $45 million in cash for 2025, indicating a substantial enhancement in profitability and cash flow, which provides financial support for future investments and expansion.
- Clinical Trial Progress: The completion of enrollment in the LeAAPS clinical trial with over 6,500 patients and the initiation of the BoxX-NoAF trial are expected to provide critical data for future product development and market promotion, further solidifying AtriCure's market position.
- Optimistic Outlook: Management projects revenue growth of 12% to 14% for 2026 and reaffirms an adjusted EBITDA target between $80 million and $82 million, reflecting confidence in future growth despite competitive pressures and uncertainties in international markets.
See More
